{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:24:42Z","timestamp":1794003882404,"version":"4.8.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijgc.2026.104889","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:10:44Z","timestamp":1785510644000},"page":"104889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["European Society for Medical Oncology Gynaecological Cancers Congress 2026: key scientific advances from the oral sessions"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5966-8940","authenticated-orcid":false,"given":"Let\u00edcia Vecchi","family":"Leis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Mandarano de Mattos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniceto","family":"Lopes da Silva Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2907-4605","authenticated-orcid":false,"given":"J\u00e9ssica Monteiro","family":"Vasconcellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-7594","authenticated-orcid":false,"given":"Mariana Carvalho","family":"Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Acevedo","family":"Zarzar Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0878-0876","authenticated-orcid":false,"given":"J\u00falia Chain","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia","family":"de Mello Graziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7713-0100","authenticated-orcid":false,"given":"Mariana","family":"Scaranti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.ijgc.2026.104889_bib1","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1001\/jama.2026.2248","article-title":"Endometrial cancer: a review","volume":"335","author":"Mager","year":"2026","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.ijgc.2026.104889_bib2","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ijgc.2026.104889_bib3","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijgc.2026.104889_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108096","article-title":"70O A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)","volume":"11","author":"Lee","year":"2026","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104889_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/hropen\/hoac057","article-title":"ESGO\/ESHRE\/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","volume":"2023","author":"Rodolakis","year":"2023","journal-title":"Hum Reprod Open"},{"issue":"22","key":"10.1016\/j.ijgc.2026.104889_bib6","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-22-3915","article-title":"Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study","volume":"29","author":"Oaknin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijgc.2026.104889_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108095","article-title":"69O six-year survival outcomes with dostarlimab monotherapy in patients (pts) with mismatch repair-deficient\/microsatellite-high (dMMR\/MSI-H) endometrial cancer (EC) in the GARNET trial","volume":"11","author":"Oaknin","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijgc.2026.104889_bib8","article-title":"PD-1 or PD-L1 inhibitors in addition to first-line chemotherapy for endometrial cancer: an extracted individual patient data meta-analysis","volume":"19","author":"Carvalho Gouveia","year":"2025","journal-title":"Ecancermedicalscience"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104889_bib9","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104889_bib10","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG-GY018 phase 3 randomized trial","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104889_bib11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104889_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108097","article-title":"71RO Sustained remission and long-term survival outcomes with dostarlimab plus chemotherapy in patients with dMMR\/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO\/GOG-3031\/RUBY trial","volume":"11","author":"Sukhin","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijgc.2026.104889_bib13","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.ygyno.2026.01.054","article-title":"Trastuzumab pamirtecan (DB-1303\/BNT323) in patients with previously treated, HER2-expressing, advanced\/metastatic endometrial cancer: first global clinical phase 2 data","volume":"208","author":"Pothuri","year":"2026","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104889_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108100","article-title":"83RO trastuzumab pamirtecan (T-Pam\/DB-1303\/BNT323) in patients (pts) with previously treated, HER2-expressing, advanced endometrial cancer (EC): overall survival (OS) and efficacy in Pt subgroups of a phase II dose-expansion cohort","volume":"11","author":"Moore","year":"2026","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104889_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2026.104792","article-title":"Expanding HER2-targeted therapeutic strategies in endometrial cancer","volume":"36","author":"Soares Pessoa","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"10333","key":"10.1016\/j.ijgc.2026.104889_bib16","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet."},{"issue":"21","key":"10.1016\/j.ijgc.2026.104889_bib17","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer","volume":"18","author":"Slomovitz","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"26","key":"10.1016\/j.ijgc.2026.104889_bib18","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.2174\/0929867321666140414095605","article-title":"Activation of PI3K\/akt\/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer","volume":"21","author":"Chen","year":"2014","journal-title":"Curr Med Chem"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104889_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000926","article-title":"Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers","volume":"5","author":"Colon-Otero","year":"2020","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104889_bib20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.22.00628","article-title":"A phase II, two-stage study of letrozole and abemaciclib in estrogen receptor-positive recurrent endometrial cancer","volume":"41","author":"Konstantinopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104889_bib21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ygyno.2024.12.003","article-title":"Palbociclib plus letrozole in estrogen receptor-positive advanced\/recurrent endometrial cancer: double-blind placebo-controlled randomized phase II ENGOT-EN3\/PALEO trial","volume":"192","author":"Mirza","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104889_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108098","article-title":"72RO Palbociclib and anastrozole for patients with estrogen receptor-positive recurrent or metastatic endometrial cancer","volume":"11","author":"Nagpal","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijgc.2026.104889_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108159","article-title":"112RO Subsequent anti-cancer therapy (SACT) of patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in ATHENA-MONO\/GOG-3020\/ENGOT-ov45","volume":"11","author":"Prendergast","year":"2026","journal-title":"ESMO Open"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104889_bib24","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 ELIMination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial","volume":"26","author":"You","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104889_bib25","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1158\/1078-0432.CCR-18-3335","article-title":"Early modeled longitudinal CA-125 kinetics and survival of ovarian cancer patients: a GINECO AGO MRC CTU study","volume":"25","author":"Colomban","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"108156","key":"10.1016\/j.ijgc.2026.104889_bib26","article-title":"109 RO Continuous relationship between KELIM chemosensitivity and survival benefit from chemotherapy intensification (standard or dose-dense; with\/without bevacizumab): ICON8","volume":"8B","author":"You","year":"2026","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104889_bib27","article-title":"Antibody-drug conjugates in platinum-sensitive ovarian cancer: beyond interval-based treatment selection?","volume":"36","author":"Mello","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104889_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103694","article-title":"Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer","volume":"9","author":"Xu-Vuillard","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijgc.2026.104889_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2026.02.026","article-title":"Mirvetuximab soravtansine plus carboplatin in folate receptor alpha-expressing recurrent platinum-sensitive ovarian cancer","volume":"208","author":"Konecny","year":"2026","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104889_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108154","article-title":"107O Mirvetuximab soravtansine (MIRV) plus carboplatin (Carbo) in folate receptor alpha (FR\u03b1)- positive platinum-sensitive ovarian cancer (PSOC): outcomes by prior poly (ADP-ribose) polymerase inhibitor (PARPi)","volume":"11","author":"Oaknin","year":"2026","journal-title":"ESMO Open"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104889_bib31","article-title":"A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FR\u03b1)-high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA\/AGO-OVAR 2.34)","volume":"44","author":"Harter","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104889_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108155","article-title":"108O A randomized phase II trial of mirvetuximab soravtansine, in folate receptor alpha (FR\u03b1) high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA\/AGO-OVAR 2.34)","volume":"11","author":"Trillsch","year":"2026","journal-title":"ESMO Open"},{"issue":"32","key":"10.1016\/j.ijgc.2026.104889_bib33","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1080\/14796694.2024.2372241","article-title":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FR\u03b1-high platinum-sensitive ovarian cancer","volume":"20","author":"O\u2019Malley","year":"2024","journal-title":"Future Oncol."},{"issue":"23","key":"10.1016\/j.ijgc.2026.104889_bib34","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ijgc.2026.104889_bib35","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2024.01.045","article-title":"Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer","volume":"185","author":"Richardson","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104889_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108158","article-title":"111RO Overview of pneumonitis in patients (pts) with folate receptor alpha (FR\u03b1)- expressing platinum-sensitive ovarian cancer (PSOC) receiving mirvetuximab soravtansine (MIRV) plus carboplatin (Carbo)","volume":"11","author":"Banerjee","year":"2026","journal-title":"ESMO Open"},{"issue":"36","key":"10.1016\/j.ijgc.2026.104889_bib37","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.24.00668","article-title":"Atezolizumab combined with platinum and maintenance niraparib for recurrent ovarian cancer with a platinum-free interval >6 months: ENGOT-OV41\/GEICO 69-O\/ANITA phase III trial","volume":"42","author":"Gonz\u00e1lez-Mart\u00edn","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104889_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108026","article-title":"1RO Validation of a prognostic circulating immune protein signature and exploratory dynamic biomarker analyses from the phase III Anita (ENGOT-Ov41\/GEICO 69-O) trial in recurrent ovarian cancer (OC)","volume":"11","author":"Gonz\u00e1lez-Mart\u00edn","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijgc.2026.104889_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108052","article-title":"26O Maintenance dostarlimab after chemoradiation (CRT) for patients (pts) with high-risk locally advanced cervical cancer (LACC): GEICO 78-C\/ATOMICC randomised phase II trial","volume":"11","author":"Oaknin","year":"2026","journal-title":"ESMO Open"},{"issue":"10434","key":"10.1016\/j.ijgc.2026.104889_bib40","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104889_bib41","article-title":"The evolving landscape of locally advanced cervical cancer treatment","volume":"35","author":"Gouveia","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.104889_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108053","article-title":"27O Long-term survival outcomes and immune subgroup analyses in the COLIBRI study: induction nivolumab plus ipilimumab with immunotherapy maintenance (ICB) prior to and following chemoradiation (RT-CT) in locally advanced cervical cancer (LACC)","volume":"11","author":"Lobbedez","year":"2026","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104889_bib43","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/s41467-025-67646-z","article-title":"Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial","volume":"17","author":"Ray-Coquard","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijgc.2026.104889_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102453","article-title":"Co-expression of tissue factor, TROP2, and NECTIN4 in primary and matched metastatic cervical cancer lesions","volume":"59","author":"Ulvang","year":"2025","journal-title":"Transl Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104889_bib45","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2025.04.009","article-title":"Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I\/II study","volume":"36","author":"Zhang","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2026.104889_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108054","article-title":"28RO Bulumtatug fuvedotin (BFv, 9MW2821), a nectin-4 antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: updated results from a phase I\/II study","volume":"11","author":"Yang","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijgc.2026.104889_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108062","article-title":"36P Preliminary results of bulumtatug fuvedotin (BFv, 9MW2821) in combined with toripalimab in patients with recurrent or metastatic cervical cancer: a cohort from a phase Ib\/II clinical study","volume":"11","author":"Lou","year":"2026","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104889_bib48","article-title":"BEHOLD-1: a phase 1 dose escalation study of GSK5733584, a B7-H4-targeted antibody-drug conjugate","volume":"85","author":"McKean","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijgc.2026.104889_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108157","article-title":"110RO Mocertatug rezetecan (Mo-Rez), a B7-H4-targeted antibody-drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): additional data from BEHOLD-1 study","volume":"11","author":"Ray-Coquard","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijgc.2026.104889_bib50","doi-asserted-by":"crossref","first-page":"S454","DOI":"10.1016\/j.ygyno.2026.02.027","article-title":"Mocertatug rezetecan (GSK5733584), a B7-H4-targeted antibody-drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): First results from the global BEHOLD-1 study","volume":"208","author":"Oaknin","year":"2026","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104889_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.108099","article-title":"73RO Histology-specific and dynamic landscapes of ADC targets in endometrial and cervical cancer: a comprehensive immunohistochemical analysis","volume":"11","author":"Shin","year":"2026","journal-title":"ESMO Open"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:33:58Z","timestamp":1794000838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26004202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1048891X26004202"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104889","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Society for Medical Oncology Gynaecological Cancers Congress 2026: key scientific advances from the oral sessions","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104889"}}